Skip to main content
LMAT logo

LeMaitre Vascular, Inc. (LMAT) Stock: Price, Forecast & Analyst Target

LeMaitre Vascular, Inc. (LMAT) — MoonshotScore 88/100 (Exceptional band), calculated Nov 18, 2026. Price $75.58 (-0.68%), as of the Nov 18, 2026 trading session; market cap $1.73B.

Educational signal · not a buy or sell recommendation · How to read this

$75.58 −$0.52 (-0.68%) Market Cap $1.73B

LeMaitre Vascular, Inc. · LMAT · NASDAQ

LeMaitre Vascular, Inc. specializes in medical devices and implants for peripheral vascular disease. Their diverse product portfolio and direct sales model contribute to a strong market presence.

Price as of Nov 18, 2026

Key Statistics

88 of 100

MoonshotScore v2 · LeMaitre Vascular (LMAT)

Exceptional
Business Quality Elite (90)
Financial Safety Fortress (89)
Valuation Full (47)
Growth Durability Compounding (88)
Momentum Quiet (59)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and elite growth, but a full valuation. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.

  • quarterly revenue $68M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z 6.80 · Piotroski F 6

Helping: business quality, balance-sheet strength, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LMAT (57 recorded, newest six shown)
RecordedScoreBand
91Exceptional
84Exceptional
84Exceptional
84Exceptional
88Exceptional
88Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$75.58
Change on the day-0.68%
52-week range$75.58 – $118.01
Market capitalisation$1.73B—
Price / earnings (trailing)27.28
Shares traded on the day222.7K

Price & events

Other perspectives

Council score for LeMaitre Vascular (LMAT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Strong
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Moderate
Debt/Equity Neutral
ROE Moderate
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is LeMaitre Vascular (LMAT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. LeMaitre Vascular, Inc. (LMAT) is listed on NASDAQ. It employs 651 people and is led by George W. LeMaitre. In Q3 FY2026 it reported revenue of $68M and net income of $15M. The market values it at $1.73B.

2 · Latest results

What do the latest results show for LeMaitre Vascular (LMAT)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $68M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$68M$15M$0.65 (diluted)
Q2 FY2026$70M$17M$0.74 (diluted)
Q1 FY2026$67M$16M$0.68 (diluted)
Q4 FY2025$64M$16M$0.68 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for LeMaitre Vascular (LMAT)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth as strengths. The distress and quality screens read Altman Z 6.80 · Piotroski F 6. Trailing ratios: ROE 15.6% · ROA 6.6% · current ratio 14.60.

4 · What to check next?

What should you watch next at LeMaitre Vascular (LMAT)?

Short answer · as of

Current published price targets run low $86.00 · high $110.00 · consensus $97.00 · median $95.00 against a quoted price of $75.58 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does LeMaitre Vascular compare with its peers?

Short answer

LeMaitre Vascular's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
AtriCure, Inc. (ATRC) Same industry, near in market value$55.45 Nov 18, 2026$2.82B95 5-pillar Nov 18, 2026
LeMaitre Vascular (LMAT) — this page$75.58$1.73B88
Haemonetics Corporation (HAE) Same industry, near in market value$122.86 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$85.93 Nov 18, 2026$5.15B81 5-pillar Nov 18, 2026
STAAR Surgical Company (STAA) Same industry, near in market value$25.35 Nov 18, 2026$1.27B80 5-pillar Nov 18, 2026
Stevanato Group S.p.A. (STVN) Same industry, near in market value$15.36 Nov 18, 2026$4.20B73 5-pillar Nov 18, 2026
ICU Medical, Inc. (ICUI) Same industry, near in market value$178.48 Nov 18, 2026$4.46B73 5-pillar Nov 18, 2026
Azenta, Inc. (AZTA) Same industry, near in market value$48.69 Nov 18, 2026$2.03B64 5-pillar Nov 18, 2026
Warby Parker Inc. (WRBY) Same industry, near in market value$28.22 Nov 18, 2026$3.51B62 5-pillar Nov 18, 2026
Jin Medical International Ltd. (ZJYL) Same industry, near in market value$3.36 Nov 18, 2026$535M41 5-pillar Nov 18, 2026
AngioDynamics, Inc. (ANGO) Same industry, near in market value$11.32 Nov 18, 2026$476M37 5-pillar Nov 18, 2026
DENTSPLY SIRONA Inc. (XRAY) Same industry, near in market value$8.52 Nov 18, 2026$1.70B31 5-pillar Nov 18, 2026
Pulse Biosciences, Inc. (PLSE) Same industry, near in market value$45.83 Nov 18, 2026$3.37B27 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$86.00 – $110.00
Consensus target
$97.00
Median target
$95.00

Consensus record · Captured .

Measured against a quoted price of $75.58 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 3, 2026

Transactions
108
Identified insiders
9
Purchases
0
Sales
0
Other transactions
108

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LMAT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LMAT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about LeMaitre Vascular (LMAT)?

Read these with our analysis →

Investor Questions: LMAT Stock

These answers are editorial: 1 of these 9 answers is drawn from the LMAT research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for LMAT?

LMAT carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. LeMaitre Vascular, Inc. specializes in medical devices and implants for peripheral vascular disease.

Is LMAT a good stock to buy?

Stock Expert AI does not rate LMAT buy, sell or hold. LeMaitre Vascular, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LMAT stock price today?

The last price recorded for LeMaitre Vascular, Inc. (LMAT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LMAT price target?

The analyst consensus price target for LeMaitre Vascular, Inc. (LMAT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does LeMaitre Vascular, Inc. do?

LeMaitre Vascular, Inc. specializes in the design, marketing, and sale of medical devices and implants used in the treatment of peripheral vascular disease.

What are the key factors to evaluate for LMAT?

LeMaitre Vascular, Inc. (LMAT) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.

How frequently does LMAT data refresh on this page?

LMAT's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LMAT's recent stock price performance?

LeMaitre Vascular, Inc. (LMAT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in vascular surgery. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LMAT overvalued or undervalued right now?

The trailing P/E of LeMaitre Vascular, Inc. (LMAT) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 21 figures on this page — 13 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.